Antipsychotics are medicines primarily used to treat psychotic symptoms and several disorders in which psychosis, severe mood disturbance or behavioural dysregulation can occur. Psychosis can involve hallucinations, delusions, disorganised thinking and other disturbances in perception or interpretation of reality, and Antipsychotics can reduce several of these symptoms by modifying neurotransmitter signalling in the brain. The medicines are commonly divided into first-generation and second-generation groups, although the distinction is imperfect because individual drugs differ substantially.
Most Antipsychotics have significant effects on dopamine receptors, while many newer medicines also affect serotonin receptors and other neurotransmitter systems. They are used in schizophrenia and related disorders, acute mania and certain severe behavioural or mood presentations, and some have additional indications. Their benefits must be balanced against neurological, metabolic, cardiovascular and other adverse effects, making dose, duration and individual risk factors important.
Dopamine D2 receptor antagonism or partial agonism is central to the pharmacology of many Antipsychotics. Excessive dopamine signalling in some neural pathways is associated with positive psychotic symptoms, and reducing D2 signalling can lessen hallucinations and delusions. However, dopamine pathways also participate in movement, motivation, endocrine regulation and other functions, which helps explain adverse effects. First-generation medicines vary in their receptor potency and can produce extrapyramidal symptoms, including dystonia, akathisia, parkinsonism and tardive dyskinesia. Second-generation medicines generally have more complex receptor profiles, often involving serotonin as well as dopamine, but they are not free of movement-related adverse effects. Some can produce substantial metabolic effects such as weight gain, dyslipidaemia and glucose abnormalities.
Antipsychotics differ in clinical profile, potency, duration and adverse-effect pattern. Some are relatively more sedating, while others have stronger effects on particular receptor systems. Long-acting injectable formulations can provide sustained medicine exposure and may be useful when maintaining consistent treatment is clinically appropriate. Oral medicines permit flexible dosing and rapid changes but depend on regular administration. Some Antipsychotics require specialised blood monitoring because of potentially serious adverse effects affecting blood cells. Others require attention to cardiac electrical activity or metabolic parameters. These differences mean that choosing an Antipsychotic involves much more than selecting a generic “strength”; the relevant medicine must be matched to symptoms, previous response, adverse-effect vulnerability, comorbidities, interactions and practical treatment requirements.
Antipsychotics are especially effective for positive psychotic symptoms such as hallucinations and delusions, but their effects on negative symptoms and cognitive impairment are generally more limited. Negative symptoms can include reduced motivation, diminished emotional expression and social withdrawal, while cognitive difficulties can affect attention, memory and executive function. Improvement in positive symptoms does not necessarily imply complete recovery of functioning. Antipsychotics may also be used during acute mania, where psychosis, severe agitation or mood elevation can require rapid pharmacological control. Some medicines have evidence for maintenance treatment or relapse prevention. Treatment goals should therefore distinguish symptom reduction, prevention of recurrence, restoration of functioning and management of adverse effects.
Extrapyramidal adverse effects are an important feature of Antipsychotic pharmacology. Acute dystonia can involve sustained muscle contractions, while akathisia produces an uncomfortable sense of inner restlessness. Drug-induced parkinsonism can resemble features of Parkinson disease, and tardive dyskinesia can involve persistent involuntary movements that may emerge after prolonged exposure. Neuroleptic malignant syndrome is a rare but potentially life-threatening reaction involving severe rigidity, altered mental status, autonomic instability and other features. Risk varies among medicines and with dose and individual factors. Monitoring for new movement abnormalities and other adverse effects is therefore important during treatment. Metabolic complications, including weight gain and disturbances in glucose and lipid regulation, are particularly relevant with some second-generation medicines and can influence long-term cardiovascular health.
Antipsychotics can interact with other medicines through pharmacodynamic and pharmacokinetic mechanisms. Combining several sedating agents can increase impairment, while medicines affecting cardiac conduction can increase the risk of clinically significant rhythm abnormalities when combined with susceptible Antipsychotics. Enzyme-inducing or enzyme-inhibiting medicines can change blood concentrations of particular drugs. Smoking can also alter the metabolism of some Antipsychotics through induction of specific hepatic enzymes, meaning that changes in smoking status can sometimes affect drug exposure. Older adults with dementia represent a particularly important safety population because Antipsychotic use in this setting is associated with increased risks and requires careful consideration of alternatives, indication and duration.
Treatment with Antipsychotics should not be interpreted as evidence that every unusual experience is caused by a permanent psychiatric disorder. Psychotic symptoms can occur in several psychiatric, neurological, toxic, metabolic and medical conditions. Assessment of the underlying cause is therefore essential. Antipsychotics can suppress symptoms without necessarily treating every underlying cause, and abrupt discontinuation after sustained treatment can increase the risk of withdrawal phenomena or relapse. Decisions about reducing or changing treatment depend on the individual clinical context. The benefits of long-term maintenance can be substantial for some people with recurrent psychotic disorders, while others may experience significant adverse effects, so treatment requires continuing evaluation rather than a one-size-fits-all approach.
The development of Antipsychotics transformed treatment of severe psychotic disorders and subsequently expanded through increasingly diverse receptor profiles and formulations. Modern understanding recognises that psychosis involves complex neural networks rather than a single neurotransmitter abnormality. Antipsychotics remain important but do not constitute the entirety of care. Psychological interventions, social support, rehabilitation, physical-health monitoring and treatment of substance use or medical contributors may all be relevant.
Common misconceptions include believing that all Antipsychotics are interchangeable, that they simply sedate people, or that absence of hallucinations means all aspects of illness have resolved. Their pharmacology is more specific: different medicines influence multiple receptor systems, produce distinct therapeutic and adverse-effect patterns and must be selected according to the clinical problem and individual risk profile.
